Mini-reviewReview: Regulation of the cancer epigenome by long non-coding RNAs

- The human genome encodes thousands of novel long non-coding RNAs (lncRNAs).
- Many lncRNAs are dysregulated across tumor types, but their functions remain to be elucidated.
- Some lncRNAs regulate epigenetic modifications, and their dysregulations in tumors impact the epigenome.
- Could some lncRNAs be useful biomarkers or targets for therapies in cancer?

Long non-coding RNAs have emerged as highly versatile players in the regulation of gene expression in development and human disease, particularly cancer. Hundreds of lncRNAs become dysregulated across tumor types, and multiple lncRNAs have demonstrated functions as tumor-suppressors or oncogenes. Furthermore, studies have demonstrated that dysregulation of lncRNAs results in alterations of the epigenome in cancer cells, potentially providing a novel mechanism for the massive epigenomic alterations observed in many tumors. Here, we highlight and provide some illustrious examples of lncRNAs in various epigenetic regulatory processes, including coordination of chromatin dynamics, regulation of DNA methylation, modulation of other non-coding RNAs and mRNA stability, and control of epigenetic substrate availability through altered tumor metabolism. In light of all these known and emerging functions in epigenetic regulation of tumorigenesis and cancer progression, lncRNAs represent attractive targets for future therapeutic strategies in cancer.